Clinical trials: Respiratory Disorders
Pulmonary Disease, Chronic Obstructive
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT01053988
- Testing
- FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder
- Where
- 132 sites in United States, Chile and 8 more
- Volunteers
- 1,031 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI).
- Trial name
- NCT00694603
- Testing
- Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Lecia V. Sequist
Advanced Cancer
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1).
- Trial name
- NCT02805660
- Testing
- Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg
- Where
- 15 sites in United States
- Volunteers
- 83 people
- Sponsor
- Mirati Therapeutics Inc.
Cystic Fibrosis
Phase II Study of Digitoxin to Treat Cystic Fibrosis
This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD
- Trial name
- NCT00782288
- Testing
- digitoxin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Jewish Health
Influenza
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK…
- Trial name
- NCT01196988
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 59 sites in United States, Czechia and 3 more
- Volunteers
- 3,027 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Cerebral Hypoxia, Postoperative Cognitive Dysfunction
The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane
the purpose of this study is to investigate whether propofol and sevoflurane have difference effect on cerebral oxygenation .
- Trial name
- NCT01757561
- Testing
- propofol, sevoflurane
- Where
- China
- Volunteers
- 144 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Pulmonary Disease, Chronic Obstructive
The Impact of a Home-based Pulmonary Telerehabilitation Program in Acute Exacerbations of COPD
COPD impacts a significant proportion of the Veteran population. Acute exacerbations, or flare-ups, of COPD are associated with impaired muscle function and worse quality of life.
- Trial name
- NCT03997513
- Testing
- Pulmonary Telerehabilitation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- VA Office of Research and Development
Pulmonary Arterial Hypertension
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.
- Trial name
- RAPID (NCT02847260)
- Testing
- Remodulin
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Pulmonary Embolism
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total…
- Trial name
- MERCURY PE (NCT02584660)
- Testing
- Rivaroxaban, Standard-of-care
- Where
- 50 sites in United States
- Volunteers
- 114 people
- Sponsor
- Janssen Scientific Affairs, LLC
Malnutrition
COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks.
At least one fifth of patients in European hospitals are malnourished. Malnutrition is associated with negative consequences, including higher rates of complications, longer hospital stay, impaired wound healing and increased…
- Trial name
- COPD (NCT02251496)
- Testing
- In between meals snacks (Snacks-group), Oral nutrition supplement (ONS-group)
- Where
- Iceland
- Volunteers
- 34 people
- Sponsor
- University of Iceland
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Contrast Enhanced Ultrasound in COVID-19
Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion.
- Trial name
- NCT04640038
- Testing
- Sulfur hexafluoride lipid-type A microspheres
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital of Philadelphia
Idiopathic Pulmonary Fibrosis
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared…
- Trial name
- CANAL (NCT04030026)
- Testing
- NAL ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Trevi Therapeutics
Influenza
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
Primary Objective: To describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule (described in the package insert for vaccine-naïve young…
- Trial name
- NCT00858468
- Testing
- Influenza virus vaccine (2004-2005 Formulation)
- Where
- 8 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID, Corona Virus Infection
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care…
- Conditions
- COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult
- Trial name
- SAVIORII (NCT04382391)
- Testing
- gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Non-Small-Cell Lung Cancer
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of three doses of pembrolizumab (MK-3475) in adult Chinese participants with locally advanced or metastatic non-small-cell lung…
- Trial name
- NCT02835690
- Testing
- Pembrolizumab
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Perennial Allergic Rhinitis, PAR
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years…
- Trial name
- NCT01451541
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 60 sites in United States
- Volunteers
- 848 people
- Sponsor
- Sumitomo Pharma America, Inc.
Scleroderma, Interstitial Lung Disease
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection.
- Trial name
- SLSII (NCT00883129)
- Testing
- Mycophenolate mofetil, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 142 people
- Sponsor
- Michael Roth
Lung Cancer, Pulmonary Nodule, Solitary
Application of Carbon Dioxide for Identifying the Intersegmental Plane in Thoracoscopic Segmentectomy
With the increasing acceptance of routine computed tomography (CT) screenings, early-stage lung cancer detection is becoming more frequent.
- Conditions
- Lung Cancer, Pulmonary Nodule, Solitary, Segmentectomy, Pulmonary Nodule, Multiple
- Trial name
- NCT05350137
- Testing
- 100% oxygen, Carbon dioxide
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tongji Hospital
Aortic Stenosis
Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study
Currently, aortic stenosis (AS) is considered a "surgical disease" with no medical therapy available to improve any clinical outcomes, including symptoms, time to surgery, or long-term survival.
- Trial name
- ASPEN-AVR (NCT01272388)
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.